Intestinal Flora

Study Title A study to learn how Shouhui Tongbian Capsules works to relieve constipation after anorectal surgery, and explore its effects linked to gut bacteria. Why we do this study Constipation is a common problem after surgery for hemorrhoids, anal fistula and other benign anorectal diseases. It causes pain, slows wound healing and lowers quality of life. Traditional laxatives may lead to stomach pain, electrolyte problems and drug dependence. Shouhui Tongbian Capsules is a traditional Chinese herbal medicine. It can ease constipation and protect the intestinal tract at the same time. This research aims to check how well this medicine works for post-surgery constipation, whether it reduces pain, and find out its working mechanism related to gut microbiota. We also want to collect evidence for better combined traditional Chinese and Western medicine treatment in clinic. Who can take part Adults aged 18 to 75 who receive surgery for benign anorectal diseases and have constipation Fully aware of the study and willing to sign an informed consent form People with severe organ diseases, mental illness, cancer, bleeding disorders, pregnancy or other conditions will not be included. How the study works This is a prospective, randomized, controlled clinical trial. A total of 120 patients will be randomly divided into two groups (60 people each): Test group: Take Shouhui Tongbian Capsules, 2 pills three times a day for 8 weeks. Control group: Take lactulose oral solution, the common medicine for constipation. We will assess symptoms regularly before, during and after treatment. We will record constipation severity, traditional Chinese medicine symptom scores, pain scores (VAS), quality of life (SF-36), physical signs and blood test results. We will also test gut bacteria and inflammation levels to analyze the medicine's mechanism. Safety All participants will be closely monitored throughout the study. We will record any discomfort or side effects in a timely manner to ensure safety. Expected benefits This study will confirm the effectiveness and safety of Shouhui Tongbian Capsules for post-anorectal surgery constipation. It may help relieve your constipation and post-operative pain, speed up recovery and improve daily life. The results will also help doctors choose better treatments for similar patients in the future. Study timeline May - June 2026: Complete ethical review and study preparation July - September 2026: Recruit participants and start treatment Late 2026 - Early 2027: Finish data collection, analysis and paper writing

Objectives: This study aims to evaluate the clinical efficacy and safety of repetitive transcranial magnetic stimulation (rTMS) in patients with diarrhea-predominant irritable bowel syndrome (IBS-D), and to explore the potential underlying mechanisms by which rTMS alleviates clinical symptoms in IBS-D patients. Design: This is a clinical trial that uses clinical symptom scales to assess the therapeutic effect of rTMS on IBS-D patients. Meanwhile, gut microbiota and metabolite profiling, as well as the methane-hydrogen breath test, will be applied to investigate the mechanism of action from the perspectives of gut microecology, intestinal motility, and metabolism, so as to provide scientific evidence for the clinical application of rTMS in the treatment of IBS-D.

To evaluate the overall efficacy of repeated Transcranial Magnetic Stimulation(rTMS) combined with a Live Probiotic tablet (Combined Bifidobacterium, Lactobacillus, Enterococcus and Bacillus cereus Tablets, Live) in Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D) Methods: Clinical efficacy evaluation of TMS combined with Live Probiotic tablet for chronic diarrhea in IBS patients. The 400 IBS patients who meet the recruitment criteria for the clinical study will be randomized into 100 patients in rTMS combined with Live Probiotic tablet (Combined Bifidobacterium, Lactobacillus, Enterococcus and Bacillus cereus Tablets, Live), rTMS combined placebo, shamrTMS combined with Live Probiotic tablet(Combined Bifidobacterium, Lactobacillus, Enterococcus and Bacillus cereus Tablets, Live) and shamrTMS combined placebo group. Corresponding treatment was given for 2 week, rTMS group received 1 Hz/s, 20 min for 2 week; Live Probiotic tablet group received tablets orally, 150 mg three times a day for 2 week, shamrTMS group received 0 Hz/s, 20 min for 2 week; placebo group received tablets orally, 150 mg three times a day for 2 week. Clinical assessment included symptoms, stool traits, mood, and sleep. 2\. Study on the mechanism of using intestinal flora data to evaluate the treatment of chronic diarrhea in IBS patients. 30 cases each were included in the 4 groups of IBS-eligible patients, and repeated transcranial magnetic stimulation treatment was given to the patient group for 2 week, and the patient group underwent the assessment of investigating the quantity and metabolic changes of the intestinal flora in feces before and after the treatment.

This is an observational case-control study, aiming to systematically analyze the gut microbiome characteristics of patients with monoclonal gammopathy of undetermined significance (MGUS). The study will collect blood and stool samples from MGUS patients, non-MGUS patients (with similar diseases), and healthy controls, and perform multi-omics detection including microbiomics, peptidomics, and biochemical immunology. It will comprehensively analyze the abnormal features of the gut microbiome in MGUS patients, which may help provide new biomarkers and potential mechanisms for the diagnosis, prognosis evaluation, and treatment strategies of MGUS.